Flare Therapeutics Competitors and Similar CompaniesClear all

Flare Therapeutics's competitors and similar companies include CureVac, CytomX Therapeutics, Astex Pharmaceuticals and Gerot Lannach.

	Flare Therapeutics Flare Therapeutics is a company that provides precision oncology solutions. It develops molecule medicines for patients.	CureVac CureVac is a biotechnology company offering messenger RNA (mRNA) technology.	CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.	Astex Pharmaceuticals Astex Pharmaceuticals is a company dedicated to the discovery and development of small molecule therapeutics with a focus on oncology.	Gerot Lannach Gerot Lannach is a pharmaceutical company that develops, produces, and sells both branded products and generics.
Founding Date	Founding Date 2021	Founding Date 2000	Founding Date 2008	Founding Date 1991	Founding Date 1947
Type	Type Private	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare biotech drug development oncology therapy	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Cambridge, US HQ	Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US	Locations South San Francisco, US HQ	Locations Pleasanton, US HQ Cambridge, GB	Locations Lannach, AT HQ Lannach, AT Wien, AT Sofia, BG Hamburg, DE Budapest, HU Rīga, LV see more
Employees	Employees 731% decrease	Employees 82517% decrease	Employees 15815% increase	Employees 512% decrease	Employees 3401% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) 648.3 m	Valuation ($) 78 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €535.2m (FY, 2024)	Revenue (est.) $76.2m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Net income	Net income N/A	Net income €162.2m (FY, 2024)	Net income ($17.4m) (FY, 2025)	Net income N/A	Net income N/A
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products 3 (May, 2020)	Phase I Trials Products 1 (FY, 2016)	Phase I Trials Products N/A	Phase I Trials Products N/A
Funding
Total funding raised	Total funding raised $ 82m	Total funding raised $ 1.1b	Total funding raised $ 132.4m	Total funding raised N/A	Total funding raised N/A